Author:
Ilieva Kristina M.,Fazekas-Singer Judit,Achkova Daniela Y.,Dodev Tihomir S.,Mele Silvia,Crescioli Silvia,Bax Heather J.,Cheung Anthony,Karagiannis Panagiotis,Correa Isabel,Figini Mariangela,Marlow Rebecca,Josephs Debra H.,Beavil Andrew J.,Maher John,Spicer James F.,Jensen-Jarolim Erika,Tutt Andrew N.,Karagiannis Sophia N.
Funder
Breast Cancer Now
Cancer Research UK
Boehringer Ingelheim Fonds
Medical Research Council
Austrian Science Fund
Academy of Medical Sciences
National Institute for Health Research
Subject
Immunology,Immunology and Allergy
Reference76 articles.
1. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2;Cuello;Cancer Res,2001
2. Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies;Fu;MAbs,2014
3. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy;Mitri;Chemother Res Pract,2012
4. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells;Molina;Cancer Res,2001
5. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献